Impaired humoral and cellular response to primary COVID‐19 vaccination in patients less than 2 years after allogeneic bone marrow transplant

Allogeneic haematopoietic stem cell transplant (HSCT) recipients remain at high risk of adverse outcomes from coronavirus disease 2019 (COVID‐19) and emerging variants. The optimal prophylactic vaccine strategy for this cohort is not defined. T cell‐mediated immunity is a critical component of graft...

Descripción completa

Detalles Bibliográficos
Autores principales: Murray, Sam M., Barbanti, Maria, Campbell, Cori, Brown, Anthony, Chen, Lucia, Dhanapal, Jay, Tseu, Bing, Pervaiz, Omer, Peters, Louis, Springett, Sally, Danby, Robert, Adele, Sandra, Phillips, Eloise, Malone, Tom, Amini, Ali, Stafford, Lizzie, Deeks, Alexandra S., Dunachie, Susanna, Klenerman, Paul, Peniket, Andrew, Barnes, Eleanor, Kesavan, Murali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348196/
https://www.ncbi.nlm.nih.gov/pubmed/35655410
http://dx.doi.org/10.1111/bjh.18312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348196/
https://www.ncbi.nlm.nih.gov/pubmed/35655410
http://dx.doi.org/10.1111/bjh.18312

Ejemplares similares